PeptideWise

Blood Work Before and During Peptide Therapy: Which Labs You Need

PeptideWise Editorial Team

Lab work is the foundation of safe peptide therapy. Without baseline markers, you cannot meaningfully assess whether a peptide protocol is helping, doing nothing, or causing harm. This guide covers which panels to request, why each marker matters, and how often to retest.

If you are considering peptide therapy under medical supervision, lab work is not optional — it is the single most important safety tool you have. Blood tests before starting a protocol establish your individual baseline, and follow-up labs reveal whether the peptide is producing measurable physiological changes, whether those changes are within safe ranges, and whether any organ systems are being stressed in ways you cannot feel.

This guide covers the lab panels that are most commonly recommended before and during peptide therapy, organized by category. Your physician may add or subtract from these based on your individual health history, but these panels represent a reasonable starting framework for discussion with your provider.

Universal Baseline Panels

Regardless of which peptide category you are exploring, certain lab panels provide foundational information that every provider should review before initiating any protocol.

Complete Blood Count (CBC)

A CBC measures the cellular components of your blood — red blood cells, white blood cells, and platelets. This panel matters for peptide therapy because:

  • Red blood cell indices (hemoglobin, hematocrit, RBC count) establish your oxygen-carrying baseline. Some peptides, particularly those that affect growth hormone pathways, may influence erythropoiesis over time.
  • White blood cell differential provides a snapshot of immune function. This is especially relevant for immune-modulating peptides like thymosin alpha-1 or LL-37.
  • Platelet count is important for anyone receiving injectable compounds, as it affects bleeding and healing at injection sites.

Comprehensive Metabolic Panel (CMP)

The CMP covers kidney function, liver function, electrolytes, and blood glucose — all organ systems that may be affected by bioactive peptides:

  • Liver enzymes (ALT, AST, ALP) — your liver metabolizes many compounds, and elevated enzymes can indicate stress or damage. Baseline values are essential because you need to know whether any elevation during therapy is new or pre-existing.
  • Kidney markers (BUN, creatinine, eGFR) — peptides and their metabolites are cleared through the kidneys. Impaired kidney function may affect dosing considerations and clearance rates.
  • Fasting glucose — multiple peptide categories can influence glucose metabolism. A baseline fasting glucose is necessary to detect changes during therapy.
  • Electrolytes (sodium, potassium, calcium, CO2) — imbalances can interact with peptide effects on fluid balance and cellular signaling.

Lipid Panel

A standard lipid panel (total cholesterol, LDL, HDL, triglycerides) provides cardiovascular baseline data. This is relevant because:

  • Some growth hormone-related peptides may influence lipid metabolism
  • GLP-1 receptor agonist peptides have demonstrated effects on triglycerides and cardiovascular markers in clinical studies
  • Lipid changes during therapy may indicate metabolic shifts that warrant attention

Hemoglobin A1c (HbA1c)

While fasting glucose provides a single-point measurement, HbA1c reflects average blood glucose over the preceding 2 to 3 months. This is a more stable and informative marker for tracking glucose metabolism changes during peptide therapy, particularly for protocols lasting several months.

Fasting Insulin

Fasting insulin, combined with fasting glucose, allows calculation of the HOMA-IR index — a measure of insulin resistance. This is particularly relevant for growth hormone-releasing peptides and GLP-1 agonists, both of which interact with insulin signaling pathways.

Thyroid Panel (TSH, Free T4, Free T3)

Growth hormone and thyroid function are interconnected. Changes in growth hormone levels may affect thyroid hormone conversion and metabolism. A baseline thyroid panel ensures that any symptoms emerging during peptide therapy (fatigue, weight changes, temperature sensitivity) can be evaluated in context.

Peptide-Category-Specific Monitoring

Beyond the universal panels, certain peptide categories require additional markers to monitor their specific physiological effects.

Growth Hormone-Releasing Peptides (CJC-1295, Ipamorelin, Sermorelin, MK-677)

Peptides that stimulate growth hormone secretion require monitoring of the growth hormone axis and its downstream effects:

  • IGF-1 (Insulin-like Growth Factor 1): This is the primary monitoring marker for growth hormone-related peptides. IGF-1 is produced by the liver in response to growth hormone and mediates many of GH's effects. Baseline IGF-1 establishes your starting point, and follow-up levels indicate whether the peptide is meaningfully stimulating GH secretion. Importantly, IGF-1 levels that exceed the age-adjusted reference range may indicate excessive stimulation and warrant dose adjustment or discontinuation.
  • Fasting glucose and insulin: Growth hormone has counter-regulatory effects on insulin, meaning it may reduce insulin sensitivity. Monitoring glucose and insulin throughout a GH-peptide protocol is essential, particularly for individuals with pre-existing insulin resistance or prediabetes.
  • HbA1c: Recheck at 3-month intervals to catch gradual shifts in glucose metabolism that single fasting glucose measurements might miss.

For MK-677 specifically, glucose monitoring is especially important. As a ghrelin mimetic, MK-677 may increase appetite and has been associated with elevations in fasting glucose and insulin resistance in some studies. Some providers also monitor prolactin, as MK-677 may affect prolactin levels in a subset of users.

Recovery and Tissue-Repair Peptides (BPC-157, TB-500)

Peptides in the recovery category have less well-characterized systemic effects than GH-releasing peptides, largely because human clinical data is limited. Recommended monitoring includes:

  • CBC and CMP: Standard safety panels to detect any unexpected hematological or metabolic changes.
  • CRP (C-Reactive Protein): An inflammatory marker that may help track whether a recovery-oriented peptide protocol correlates with changes in systemic inflammation. High-sensitivity CRP (hs-CRP) is preferred for detecting subtle changes.
  • Liver enzymes: Particularly if peptides are administered systemically rather than locally.

Because the evidence base for these peptides is predominantly preclinical, there are no established clinical monitoring guidelines. The panels above represent a reasonable safety-first approach rather than an evidence-derived standard.

Immune-Modulating Peptides (Thymosin Alpha-1, LL-37)

Peptides that influence immune function require monitoring of immune markers:

  • CBC with differential: Changes in lymphocyte subsets, neutrophil counts, or overall white blood cell counts may reflect immune modulation.
  • CRP and ESR (Erythrocyte Sedimentation Rate): Inflammatory markers that can indicate whether immune modulation is producing pro- or anti-inflammatory effects.
  • Immunoglobulin levels (IgA, IgG, IgM): May be relevant for individuals with autoimmune conditions or immunodeficiencies. Your provider may add these based on your clinical picture.

GLP-1 Receptor Agonist Peptides

For FDA-approved GLP-1 medications like semaglutide and tirzepatide, monitoring guidelines are better established through clinical trial data and prescribing information:

  • HbA1c and fasting glucose: Core efficacy markers for metabolic effects.
  • Lipid panel: GLP-1 agonists may improve triglyceride levels and other cardiovascular markers.
  • Kidney function (eGFR, creatinine): GLP-1 medications may cause dehydration through appetite suppression and nausea, which can stress kidney function.
  • Lipase and amylase: Some providers monitor pancreatic enzymes due to the theoretical association between GLP-1 agonists and pancreatitis, though the clinical significance of mildly elevated lipase without symptoms remains debated.
  • Thyroid function: A precautionary measure given the signal for thyroid C-cell tumors observed in rodent studies with GLP-1 agonists, though clinical relevance in humans has not been established.

Hormone Panel Considerations

Depending on your age, sex, and the peptide category, your provider may also recommend baseline hormone testing:

  • Testosterone (total and free): Relevant for growth hormone-related peptides, as GH and testosterone interact in anabolic pathways.
  • Estradiol: Growth hormone may influence estrogen metabolism. Baseline values provide context for any changes observed during therapy.
  • Cortisol (AM fasting): Relevant for peptides that may affect the HPA axis, and useful for distinguishing peptide effects from stress-related hormonal changes.
  • DHEA-S: An adrenal marker that some providers include as part of a comprehensive hormonal baseline.

Testing Frequency: When to Retest

Baseline labs are only useful if followed by appropriately timed retesting. The following schedule represents a general framework — your provider may adjust based on your individual results and clinical picture.

Pre-Protocol (Baseline)

All applicable panels should be drawn before starting any peptide protocol. Ideally, these are fasting morning draws, as many markers (glucose, insulin, cortisol, testosterone) have diurnal variation that morning testing standardizes.

4 to 6 Weeks After Starting

The first follow-up panel is typically the most important. At this point:

  • Repeat the CMP and fasting glucose to check liver and kidney function under the new protocol
  • Check IGF-1 if using GH-releasing peptides — this is when you expect to see initial changes
  • Review CBC for any unexpected shifts
  • Assess whether any subjective side effects correlate with objective lab changes

3 Months

At the three-month mark, recheck:

  • HbA1c — now reflects the full period of peptide use
  • IGF-1 — should be stable; levels continuing to rise may indicate a need for dose adjustment
  • Full CMP and lipid panel
  • Thyroid panel if using GH-releasing peptides
  • CRP if tracking inflammation

6 Months and Ongoing

For longer protocols, a comprehensive panel every 3 to 6 months is a reasonable cadence. This should include all baseline markers plus any peptide-specific additions. Consistency matters — testing at the same time of day, in the same fasting state, and ideally at the same lab, improves the comparability of results over time.

When to Test Immediately

Outside of the scheduled testing cadence, lab work should be ordered promptly if:

  • You experience symptoms suggesting liver stress (upper right abdominal pain, dark urine, jaundice)
  • You notice significant changes in urination, thirst, or signs of blood sugar dysregulation
  • You develop unexplained swelling, particularly in extremities (may indicate fluid retention from GH-related peptides)
  • Any new or concerning symptoms arise that your provider wants to evaluate objectively

Practical Tips for Lab Testing

  • Fast for 12 hours before morning draws. Water is fine; coffee and supplements should be avoided as they can affect glucose, insulin, and liver enzyme readings.
  • Test at the same time of day. Many hormones and metabolic markers fluctuate throughout the day. Consistent timing makes results comparable.
  • Use the same lab. Reference ranges and assay methods vary between laboratories. Using the same lab for all your panels eliminates this variable.
  • Keep copies of every result. Building a longitudinal record allows you and your provider to spot trends that a single snapshot would miss. Apps like PeptideTracker can help organize this data over time.
  • Discuss results in context. A single out-of-range value is not necessarily alarming — context, trends, and clinical symptoms all matter. Your provider is the right person to interpret whether a result is clinically significant or a normal variation.

What Lab Work Cannot Tell You

Lab work is essential, but it has limitations. Blood tests measure circulating biomarkers, which may not fully reflect what is happening at the tissue level. A normal IGF-1 level does not guarantee that a GH-releasing peptide is producing the local effects you are hoping for. A normal CRP does not mean a tissue-repair peptide is accelerating healing at a specific injury site.

Lab work is a safety tool and a general indicator of systemic response. It complements — but does not replace — clinical assessment, symptom tracking, and honest communication with your healthcare provider about what you are experiencing.

This article is for informational and educational purposes only. Nothing here constitutes medical advice, treatment recommendation, or encouragement to use any substance without appropriate medical supervision. Lab testing should be ordered and interpreted by a licensed healthcare provider who understands your individual health context.